"When we licensed paxalisib from Genentech in 2016, we did not fully anticipate what a large role it would play in the company’s evolution. That it has done so is a reflection of its exceptional pedigree and the enormous potential that the drug has since demonstrated.
Quite simply, it has proven to be a much more promising asset than even we realised at the time."
Ann: Chairman's Address to Shareholders, page-5
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)